Glaxo
Executive Summary
Will develop camptothecin analogs under an exclusive worldwide licensing agreement with the independent research organization Research Triangle Institute announced Aug. 29. The synthetic analogs, which are based on a compound isolated from a Chinese tree, (ITALICS)Camptotheca auminata,(END ITALICS) have shown promise in inhibiting an enzyme required for cell replication and may therefore have potential as anticancer agents. In return for worldwide rights, Glaxo will provide RTI funds to support research and pay royalties on eventual product sales.